media – Page 19 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Aohua Endoscope, Enters the Medical Robot Industry

Recently, Aohua Endoscope has successfully obtained an invention patent authorization called “Endoscope Trolley and Medical Robot”, with patent application number CN202210369876.8. It is reported that this patent effectively reduces the physical exertion of operators through rich operating functions, which will further enhance the company’s technological advantages in the field of soft endoscopes. As a company with over 30 years of development history, Aohua Endoscope’s product layout covers soft mirrors, hard mirrors, and diagnostic and therapeutic consumables. Its diversified layout from upstream to downstream is continuously enhancing its influence in the industry. 01. Obtained patents for endoscope trolleys and medical robots According to the patent abstract, the present invention provides an endoscope trolley and a medical robot. The endoscope trolley comprises a trolley body, a first telescopic arm, and a second telescopic arm. The trolley body comprises a base and a worktable. The worktable is installed on the base in a ...
- Source: drugdu
- 76
- March 13, 2025
The world’s first! One innovative medical device has obtained FDA breakthrough device certification

Recently, NextBioMedical announced that its absorbable embolic microsphere, Nexsphere-F, has been awarded the “Breakthrough Device” designation by the FDA. At present, Nexsphere-F has been approved for CE, and it is worth mentioning that this product is also the only CE approved microsphere for the treatment of musculoskeletal pain embolism. Innovative technology, breaking through traditional boundaries The Nexsphere-F, which was awarded the breakthrough device this time, is an embolic microsphere with a size of 100-300 μ m that can be quickly absorbed by patients. Its indication is for the treatment of knee osteoarthritis pain in patients who do not respond adequately to conservative non pharmacological treatment and/or analgesics. It is worth mentioning that this product integrates innovative absorbable microsphere technology. When Nexsphere-F is delivered to the patient’s target blood vessel through a 1.7Fr microcatheter, the microspheres will absorb water and expand, thereby achieving precise blockage of the target blood vessel and ...
- Source: drugdu
- 88
- March 13, 2025
So far, my country has never exported fentanyl drugs to North America

On March 12, the spokesperson of the National Medical Products Administration answered reporters’ questions about the white paper “China’s Fentanyl Substance Control” and said that fentanyl drugs are mainly used for analgesia in clinical practice. Non-medical use will cause drug abuse and even lead to public health and social problems. So far, there are 4 fentanyl drugs approved for marketing in my country, namely fentanyl, sufentanil, remifentanil and alfentanil. Three companies are allowed to produce raw materials and five companies are allowed to produce preparations. In 2024, my country’s production of fentanyl raw materials will be 100 kilograms, mainly for domestic medical use and export. In 2024, my country’s fentanyl drug exports will be 12.3 kilograms (in terms of fentanyl bases), mainly exported to South Korea, Vietnam, the Philippines and other countries. To date, my country has never exported fentanyl-related drugs to North America. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 102
- March 13, 2025
Weiming Pharmaceutical plans to sign a sales contract worth 53.978 million yuan

On March 12, Weiming Pharmaceutical announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. plans to sign a “Sales Contract” with Jiangsu Soho Innovation Technology Group Co., Ltd. to purchase the liquid storage system and chromatography system, filler and reaction bags required for the Shandong Weiming Biomedicine Industrial Park project recombinant human nerve growth factor eye drops production workshop from Jiangsu Soho. The total contract price is 53.978 million yuan. The signing of this contract provides hardware guarantee for the industrialization of the company’s existing pipelines, which is conducive to further improving the company’s industrial layout and promoting the continuous growth of the company’s operating performance. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 72
- March 13, 2025
Wholly-owned subsidiary Xiantai Pharmaceutical obtains Spanish AEMPS GMP compliance certificate

On March 12, North China Pharmaceutical announced that its wholly-owned subsidiary North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. received the “Manufacturer GMP Compliance Certificate” issued by the Spanish Medicines and Medical Devices Agency. The production lines involved in the certificate include procaine penicillin series products, benzathine penicillin series products and amoxicillin (sterile), and the inspection conclusion is in compliance with EU GMP principles. Among them, the inspection of amoxicillin (sterile) is the first drug GMP compliance inspection before it is listed in the EU. Xiantai Company is the only domestic amoxicillin (sterile) manufacturer that has passed EUGMP certification. The acquisition of this certificate will have a positive impact on the sales of amoxicillin (sterile) products to the EU market, but will not have a significant impact on the company’s current operating performance. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 72
- March 13, 2025
The “One who swimming against the current” in the generic drug industry

Centralized procurement has led to a sharp drop in the price of generic drugs, which poses a direct challenge to the company’s revenue. However, key generic drug companies such as Beite Pharmaceuticals have maintained steady revenue growth under the background of centralized procurement with their strong R&D strength and market competitiveness. Data show that its sales of pharmaceutical preparations have continued to grow, with a compound growth rate of up to 30.7%, especially in 2021, which has achieved a leapfrog growth. Remarkable performance and steady growth In recent years, Chengdu Beite Pharmaceuticals’ performance has continued to grow, showing strong development resilience and potential. In 2023, the company’s sales of pharmaceutical preparations reached 7.41 billion yuan. From 2016 to 2023, the compound growth rate of sales of preparations was as high as 30.7%, especially in 2021, Beite Pharmaceuticals’ performance achieved a leapfrog growth, a year-on-year increase of 98.0% compared with 2020. ...
- Source: drugdu
- 65
- March 13, 2025
CPhI Korea

Organiser: Informa Markets Time: August 26 – 28, 2025 Address: COEX Convention & Exhibition Center, 513 Yeongdong-daero, Gangnam-gu, Seoul Exhibition hall: COEX Convention & Exhibition Center Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, Hormones, Sulfonamides, Antipyretics and Analgesics, Tetracyclines, Amino Acids and Derivatives, Chloramphenicols, Gastrointestinal Medications, Other Antiinfectives, Penicillins, Aminoglycosides, Lincomycins, Cardiovascular Medications, Antiparasitic Drugs, Cephalosporins, Macrolides, Respiratory Medications, Central Nervous System Medications, Other Pharmaceutical Raw Materials Excipients & Dosage Forms: Excipients, Glidants, Enteric Coatings, Antioxidants, Sweeteners, Penetration Enhancers, Preservatives, Disintegrants, Coating Materials, Surfactants, Opacifiers, Flavors, Filter Aids, Stabilizers, Lubricants, Plasticizers, Solvents, Taste Masking Agents, Colorants, Clarifiers, pH Adjusters, Others Natural Extracts: Plant Extracts, Animal Extracts, Traditional Chinese Medicine Ingredients, Functional Food Ingredients, Health Supplement Ingredients, Nutritional Health Ingredients, Supplements, Dietary Fibers, Cosmetic Ingredients About CPhI Korea： CPhI Korea, first held in 2014, adopts a diversified and integrated format combining “exhibition + conference” trade matchmaking. It invites relevant government officials and experts ...
- Source: drugdu
- 108
- March 13, 2025
a milestone in the rise of domestic production

In January 2025, the Guizhou Provincial Health Commission launched a centralized procurement project for CT equipment. The total budget of the project is as high as 175.25 million yuan, covering the procurement of 13 sets of CT equipment. Recently, it was announced that the total bid amount for this centralized procurement project was only 78.03 million yuan, which is 44.5% of the budget. Domestic brand CT equipment performed well, and Neusoft Medical became the biggest winner in this bidding, winning 7 sets. 01. Domestic brand wins bid as mainstream The recently announced winning bid for the CT equipment centralized procurement project by the Guizhou Provincial Health Commission shows that the total bid amount for this centralized procurement project is only 78.03 million yuan, which is only 44.5% of the budget and directly saves nearly 100 million yuan in funds. In fierce competition, domestic CT equipment brands have performed well, with ...
- Source: drugdu
- 127
- March 12, 2025
Heavy Ten Year Plan

Recently, Medtronic announced the launch of a “bold” ten-year global plan – Medtronic Spark. 01. Medtronic Spark Program: Lighting the Path to High paying Jobs for Low Income Youth Amidst the global shortage of medical talent, a grand plan aimed at cultivating future leaders in health technology is quietly underway in Galway, Ireland. Global medical technology giant Medtronic has announced the launch of its ten-year “Medtronic Spark” program, aimed at paving a path to high paying health technology careers for one million young people from low-income families. As 2030 approaches, the healthcare and technology industries are facing an unprecedented talent crisis. It is predicted that these two industries will face a total shortage of 15 million professionals, with the health technology sector alone facing a shortage of 4.3 million, and healthcare workers expected to face a huge shortage of 11 million. This severe situation poses a serious challenge to low-income ...
- Source: drugdu
- 103
- March 12, 2025
Sino Biopharmaceuticals and Qingpu Biotechnology Reach Exclusive Cooperation Agreement

Sino Biopharmaceuticals (01177.HK) announced on March 6 that the company recently reached an exclusive cooperation agreement with Nanjing Qingpu Biotechnology Co., Ltd. (hereinafter referred to as “Qingpu Biotechnology”) in mainland China for its developed national Class 2 new drug QP001. According to reports, QP001 is a meloxicam injection registered as a national Class 2 new drug. It is a long-acting, potent new non-steroidal anti-inflammatory drug (NSAIDs) for postoperative pain. Compared with traditional non-selective NSAIDs, QP001 is a selective cyclooxygenase-2 (COX-2) inhibitor that can block the release of COX-2 that causes body pain and inflammation, reduce or block the synthesis of prostaglandins (PGs) in the affected area, thereby playing an anti-inflammatory and analgesic role, while having little effect on cyclooxygenase-1 (COX-1) that maintains normal physiological functions. Therefore, in the future, patients with mild renal impairment, elderly patients and other special groups can also use it normally. China Biopharmaceuticals said that at ...
- Source: drugdu
- 86
- March 12, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.